<- Go Home
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Market Cap
$22.9M
Volume
88.1K
Cash and Equivalents
$3.7M
EBITDA
-$17.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$4.59
52 Week Low
$0.81
Dividend
N/A
Price / Book Value
0.78
Price / Earnings
-0.91
Price / Tangible Book Value
0.78
Enterprise Value
-$2.2M
Enterprise Value / EBITDA
0.13
Operating Income
-$18.7M
Return on Equity
61.17%
Return on Assets
-27.46
Cash and Short Term Investments
$25.9M
Debt
$835.0K
Equity
$28.6M
Revenue
N/A
Unlevered FCF
-$12.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium